Gene Ontology annotation through association of InterPro records with GO terms
Gene Ontology annotation based on Enzyme Commission mapping
Annotation inferences using phylogenetic trees
Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt
Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara
Automatic Gene Ontology annotation based on Rhea mapping
UniProtKB record for human LMTK2 (Q8IWU2)
-
The reviewed human record names LMTK2 a serine/threonine-protein kinase.
"DE RecName: Full=Serine/threonine-protein kinase LMTK2;"
-
UniProt summarizes PPP1C, phosphorylase b, and CFTR as LMTK2 substrates.
"CC -!- FUNCTION: Phosphorylates PPP1C, phosphorylase b and CFTR."
-
UniProt records nine IntAct experiments connecting LMTK2 with PPP1CC.
"CC Q8IWU2; P36873: PPP1CC; NbExp=9; IntAct=EBI-2008933, EBI-356283;"
-
UniProt records four IntAct experiments connecting LMTK2 with PPP1R2/inhibitor-2.
"CC Q8IWU2; P41236: PPP1R2; NbExp=4; IntAct=EBI-2008933, EBI-1056517;"
Unconventional myosin-VI (Homo sapiens)
A novel transmembrane Ser/Thr kinase complexes with protein phosphatase-1 and inhibitor-2.
-
KPI-2/LMTK2 is a membrane-targeted 1,503-residue kinase with two predicted N-terminal helices.
"KPI-2 is a 1503-residue protein with two predicted transmembrane helices at the N terminus, a kinase domain, followed by a C-terminal domain. The transmembrane helices were sufficient for targeting proteins to the membrane."
-
Human KPI-2/LMTK2 displays serine/threonine kinase activity.
"However, it only exhibited serine/threonine kinase activity in autophosphorylation reactions or with added substrates."
-
LMTK2 binds and inhibits PP1C through phosphorylation of PP1C Thr320 and also binds inhibitor-2.
"KPI-2 kinase domain phosphorylated protein phosphatase-1 (PP1C) at Thr(320), which attenuated PP1C activity. KPI-2 C-terminal domain directly associated with PP1C, and this required a VTF motif. Inh2 associated with KPI-2 C-terminal domain with and without PP1C."
Identification of a novel, membrane-associated neuronal kinase, cyclin-dependent kinase 5/p35-regulated kinase.
-
CPRK/LMTK2 binds CDK5R1/p35 and colocalizes with it at the Golgi.
"Cprk interacts with p35 in the yeast-two hybrid system, binds to p35 in glutathione S-transferase fusion pull-down assays, and colocalizes with p35 in cultured neurons and transfected cells. In these cells, cprk is present with p35 in the Golgi apparatus."
-
CDK5/p35 phosphorylates LMTK2 and inhibits its kinase activity.
"Cprk displays catalytic activity in in vitro kinase assays and is itself phosphorylated by cdk5/p35. Cdk5/p35 inhibits cprk activity."
Peptide microarray analysis of substrate specificity of the transmembrane Ser/Thr kinase KPI-2 reveals reactivity with cystic fibrosis transmembrane conductance regulator and phosphorylase.
-
Recombinant human KPI-2/LMTK2 is strictly serine/threonine-directed.
"We found that KPI-2 is strictly a Ser/Thr kinase that reacts with Ser either preceded by or followed by Pro residues but unlike other Pro-directed kinases does not strictly require an adjacent Pro residue."
-
CFTR Ser737 and the recombinant CFTR R domain are preferred in-vitro substrates.
"The most reactive peptide in the library corresponds to Ser-737 of cystic fibrosis transmembrane conductance regulator, and the recombinant R domain of cystic fibrosis transmembrane conductance regulator was a preferred substrate."
-
KPI-2 activity toward phosphorylase is reduced after NGF or serum addition.
"Phosphorylase was used as a specific substrate to show that KPI-2 is inhibited in living cells by addition of nerve growth factor or serum."
Myosin VI and its interacting protein LMTK2 regulate tubule formation and transport to the endocytic recycling compartment.
-
LMTK2 directly binds the WWY site in the unconventional myosin-VI tail.
"In this paper we have identified a new myosin-VI-binding partner, lemur tyrosine kinase 2 (LMTK2), which is the first transmembrane protein and kinase that directly binds to myosin VI. LMTK2 binds to the WWY site in the C-terminal myosin VI tail, the same site as the endocytic adaptor protein Dab2."
-
LMTK2 depletion blocks transferrin-receptor delivery from early endosomes to the recycling compartment.
"When either myosin VI or LMTK2 is depleted by siRNAs, the transferrin receptor (TfR) is trapped in swollen endosomes and tubule formation in the endocytic recycling pathway is dramatically reduced, showing that both proteins are required for the transport of cargo, such as the TfR, from early endosomes to the endocytic recycling compartment."
-
LMTK2 localizes on early endosomes and the Rab11-positive recycling compartment.
"Double labelling experiments show that LMTK2 is present on a subset of early endosomes as revealed by colocalisation with Rab5 and EEA1 (Fig. 4, d-j) and also associated with the Rab11-positive endocytic recycling compartment (Fig. 4, k-m)."
BREK/LMTK2 is a myosin VI-binding protein involved in endosomal membrane trafficking.
-
BREK/LMTK2 interacts with unconventional myosin VI in vivo and in vitro.
"Several binding experiments confirmed the interaction of myosin VI with BREK in vivo and in vitro."
-
BREK/LMTK2 localizes to cytoplasmic vesicles and perinuclear recycling endosomes.
"Immunocytochemical analyses revealed that BREK localizes to cytoplasmic membrane vesicles and to perinuclear recycling endosomes."
-
LMTK2 depletion blocks transferrin traffic after early-endosome arrival and before recycling-endosome arrival.
"Notably, cells in which BREK was depleted by siRNA were still able to internalize transferrin molecules and to transport them to early endosomes, but were unable to transport them to perinuclear recycling endosomes."
Interaction proteome of human Hippo signaling: modular control of the co-activator YAP1.
-
This is a broad Hippo-pathway protein-interaction resource.
"The resulting high-resolution network model of 480 protein-protein interactions among 270 network components suggests participation of Hippo pathway components in three distinct modules that all converge on the transcriptional co-activator YAP1."
A human interactome in three quantitative dimensions organized by stoichiometries and abundances.
-
This is a quantitative global interaction survey measuring interactions, stoichiometry, and abundance.
"Using quantitative proteomics, we detect specific interactions, estimate interaction stoichiometries, and measure cellular abundances of interacting proteins."
A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome.
-
The study explicitly cautions that its interaction pairs do not establish enzyme-substrate direction.
"However, it should be noted that these interactions are not equivalent to enzyme-substrate interactions, and therefore do not necessarily suggest that the involved phosphatase directly dephosphorylates a given RTK or, conversely, that the RTK can phosphorylate the phosphatase."
Systematic Analysis of Human Protein Phosphatase Interactions and Dynamics.
-
The study used quantitative affinity proteomics across human phosphatases and cofactors.
"Here, we used quantitative affinity proteomics to assay protein-protein interactions for 54 phosphatases distributed across the three major protein phosphatase families, with additional analysis of their 12 co-factors."
Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
-
BioPlex generated cell-line-specific human interaction networks by affinity-purification mass spectrometry.
"Through affinity-purification mass spectrometry, we have created two proteome-scale, cell-line-specific interaction networks."
Physical and functional interactome atlas of human receptor tyrosine kinases.
-
The atlas distinguishes stable, proximity, and in-vitro substrate assays.
"We use affinity purification coupled to mass spectrometry (AP-MS) to characterize stable binding partners and RTK-protein complexes, proximity-dependent biotin identification (BioID) to identify transient and proximal interactions, and an in vitro kinase assay to identify RTK substrates."
Multimodal cell maps as a foundation for structural and functional genomics.
-
The study combines interaction and imaging measurements across more than 5,100 proteins in U2OS cells.
"Here we construct a global map of human subcellular architecture through joint measurement of biophysical interactions and immunofluorescence images for over 5,100 proteins in U2OS osteosarcoma cells."
Determination of the membrane topology of lemur tyrosine kinase 2 (LMTK2) by fluorescence protease protection.
-
Both LMTK2 termini and its kinase active site face the cytoplasm.
"Our results indicate that LMTK2 is an integral membrane protein in which both the amino and carboxyl termini are exposed to the cytoplasm. Moreover, this topology places the kinase active site within the cytoplasm."
-
The study directly establishes LMTK2 topology in endosomal membranes.
"In conclusion, we have, for the first time, formally demonstrated the topology and orientation of LMTK2 within endosomal membranes."
LMTK2-mediated phosphorylation regulates CFTR endocytosis in human airway epithelial cells.
-
LMTK2 associates with CFTR and phosphorylates CFTR Ser737 in human airway epithelia.
"Here we demonstrate that LMTK2 co-immunoprecipitates with CFTR and phosphorylates CFTR-Ser(737) in human airway epithelial cells."
-
LMTK2 kinase activity promotes CFTR endocytosis and thereby lowers its surface abundance.
"LMTK2 knockdown or expression of inactive LMTK2 kinase domain increases cell surface density of CFTR by attenuating its endocytosis in human airway epithelial cells."
Signal dependent ER export of lemur tyrosine kinase 2.
-
A C-terminal di-acidic motif controls LMTK2 ER export, endosomal delivery, and transferrin recycling.
"Mutation of the di-acidic export motif led to ER retention of LMTK2, and an increase in protein half-life and a concomitant loss of LMTK2 from its appropriate terminal destination. Loss of LMTK2 from endosomal compartments by preventing its release from the ER is linked to a reduction in transferrin recycling."
Cdk5/p35 phosphorylates lemur tyrosine kinase-2 to regulate protein phosphatase-1C phosphorylation and activity.
-
CDK5/p35 phosphorylates LMTK2 Ser1418 and regulates its ability to phosphorylate PP1C Thr320.
"Here, we demonstrate that LMTK2 is phosphorylated on serine-1418 (LMTK2ser¹⁴¹⁸) by cdk5/p35 and present evidence that this regulates its ability to phosphorylate PP1Cthr³²⁰."
LMTK2 binds to kinesin light chains to mediate anterograde axonal transport of cdk5/p35 and LMTK2 levels are reduced in Alzheimer's disease brains.
-
A C-terminal LMTK2 WD motif binds KLC1/2 TPR domains and supports LMTK2 axonal transport.
"Binding to KLC1/2 involves a C-terminal tryptophan/aspartate (WD) motif in LMTK2 and the tetratricopeptide repeat (TPR) domains in KLC1/2, and this interaction facilitates axonal transport of LMTK2."
-
LMTK2 connects KLC1 with p35 and is required for p35/CDK5 axonal transport.
"We also show that LMTK2 facilitates the formation of a complex containing KLC1 and p35 and that siRNA loss of LMTK2 disrupts axonal transport of both p35 and cdk5."
Azoospermia in mice with targeted disruption of the Brek/Lmtk2 (brain-enriched kinase/lemur tyrosine kinase 2) gene.
-
Mouse Lmtk2 is required after the round-spermatid stage for spermatid elongation.
"Detailed histological analysis revealed that Brek(-/-) germ cells differentiated normally until the round-spermatid stage, but failed to undergo the normal change in morphology to become elongated spermatids."
-
Mouse knockout establishes a late-spermatogenesis requirement.
"On the basis of these findings, we concluded that Brek is essential for a late stage of spermatogenesis."
Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo.
-
LMTK2 signals through PP1C and GSK3β to reduce KLC2 phosphorylation and increase Smad2 cargo binding.
"LMTK2 signals via protein phosphatase-1C (PP1C) to increase inhibitory phosphorylation of GSK3β on serine-9 that reduces KLC2 phosphorylation and promotes binding of the known KLC2 cargo Smad2."
-
Endogenous LMTK2 depletion impairs KLC2-Smad2 binding and TGF-β-induced Smad2 signaling.
"We show that small interfering RNA loss of LMTK2 not only reduces binding of Smad2 to KLC2, but also inhibits TGFβ-induced Smad2 signalling."
LMTK2 switches on canonical TGF-β1 signaling in human bronchial epithelial cells.
-
LMTK2-dependent PP1C inhibition enables canonical Smad3 signaling in human bronchial epithelia.
"Second, TGF-β1 inhibited PP1c by an LMTK2-dependent mechanism. Third, TGF-β1 used LMTK2 to activate canonical Smad3-mediated signaling."
A revised nomenclature for the lemur family of protein kinases.
-
The field consensus recognizes LMTK proteins as serine/threonine rather than tyrosine kinases.
"However, experimental data conducted by several laboratories independently have proved that LMTK1, LMTK2 and LMTK3 solely phosphorylate serine and threonine residues and do not target tyrosine residue"
-
The consensus connects the historical KPI-2, CPRK, BREK, AATYK2, KIAA1079, and LMR2 names to LMTK2.
"For example, LMTK2 is a membrane-anchored serine/threonine kinase formerly known as kinase/phosphatase/inhibitor-2 (KPI-2), Cdk5/p35-regulated kinase (Cprk), brain-enriched kinase (BREK), apoptosis-associated tyrosine kinase-2 (AATYK2), KIAA1079 and LMR2"